Literature DB >> 22507964

Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.

Mo Chen1, Adegoke O Adeniji, Barry M Twenter, Jeffrey D Winkler, David W Christianson, Trevor M Penning.   

Abstract

Castrate resistant prostate cancer (CRPC) is associated with increased androgen receptor (AR) signaling often brought about by elevated intratumoral androgen biosynthesis and AR amplification. Inhibition of androgen biosynthesis and/or AR antagonism should be efficacious in the treatment of CRPC. AKR1C3 catalyzes the formation of potent AR ligands from inactive precursors and is one of the most upregulated genes in CRPC. AKR1C3 inhibitors should not inhibit the related isoforms, AKR1C1 and AKR1C2 that are involved in 5α-dihydrotestosterone inactivation in the prostate. We have previously developed a series of flufenamic acid analogs as potent and selective AKR1C3 inhibitors [Adeniji, A. O. et al., J. Med. Chem.2012, 55, 2311]. Here we report the X-ray crystal structure of one lead compound 3-((4-(trifluoromethyl)phenyl) amino)benzoic acid (1) in complex with AKR1C3. Compound 1 adopts a similar binding orientation as flufenamic acid, however, its phenylamino ring projects deeper into a subpocket and confers selectivity over the other AKR1C isoforms. We exploited the observation that some flufenamic acid analogs also act as AR antagonists and synthesized a second generation inhibitor, 3-((4-nitronaphthalen-1-yl)amino)benzoic acid (2). Compound 2 retained nanomolar potency and selective inhibition of AKR1C3 but also acted as an AR antagonist. It inhibited 5α-dihydrotestosterone stimulated AR reporter gene activity with an IC(50)=4.7 μM and produced a concentration dependent reduction in androgen receptor levels in prostate cancer cells. The in vitro and cell-based effects of compound 2 make it a promising lead for development of dual acting agent for CRPC. To illuminate the structural basis of AKR1C3 inhibition, we also report the crystal structure of the AKR1C3·NADP(+)·2 complex, which shows that compound 2 forms a unique double-decker structure with AKR1C3.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22507964      PMCID: PMC3348334          DOI: 10.1016/j.bmcl.2012.03.085

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  27 in total

1.  Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.

Authors:  T M Penning; M E Burczynski; J M Jez; C F Hung; H K Lin; H Ma; M Moore; N Palackal; K Ratnam
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

2.  Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.

Authors:  Michael C Byrns; Rebekka Mindnich; Ling Duan; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2012-01-12       Impact factor: 4.292

3.  Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.

Authors:  Mark A Titus; Michael J Schell; Fred B Lih; Kenneth B Tomer; James L Mohler
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

4.  Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione.

Authors:  M E Burczynski; R G Harvey; T M Penning
Journal:  Biochemistry       Date:  1998-05-12       Impact factor: 3.162

5.  The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.

Authors:  D H Harrison; K M Bohren; G A Petsko; D Ringe; K H Gabbay
Journal:  Biochemistry       Date:  1997-12-23       Impact factor: 3.162

6.  Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins.

Authors:  T M Penning; P Talalay
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

7.  Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action.

Authors:  Stephan Steckelbroeck; Yi Jin; Sridhar Gopishetty; Busola Oyesanmi; Trevor M Penning
Journal:  J Biol Chem       Date:  2003-12-12       Impact factor: 5.157

8.  Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.

Authors:  David R Bauman; Stephen I Rudnick; Lawrence M Szewczuk; Yi Jin; Sridhar Gopishetty; Trevor M Penning
Journal:  Mol Pharmacol       Date:  2004-10-08       Impact factor: 4.436

9.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

10.  Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.

Authors:  A O'Donnell; I Judson; M Dowsett; F Raynaud; D Dearnaley; M Mason; S Harland; A Robbins; G Halbert; B Nutley; M Jarman
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more
  25 in total

Review 1.  Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).

Authors:  Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2015-05-29       Impact factor: 4.292

Review 2.  Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes.

Authors:  Trevor M Penning; Phumvadee Wangtrakuldee; Richard J Auchus
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

3.  Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.

Authors:  Adegoke Adeniji; Md Jashim Uddin; Tianzhu Zang; Daniel Tamae; Phumvadee Wangtrakuldee; Lawrence J Marnett; Trevor M Penning
Journal:  J Med Chem       Date:  2016-08-12       Impact factor: 7.446

Review 4.  Mechanisms of androgen receptor activation in castration-resistant prostate cancer.

Authors:  Nima Sharifi
Journal:  Endocrinology       Date:  2013-09-03       Impact factor: 4.736

5.  Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

Authors:  Nicholas Mitsiades; Clifford C Sung; Nikolaus Schultz; Daniel C Danila; Bin He; Vijay Kumar Eedunuri; Martin Fleisher; Chris Sander; Charles L Sawyers; Howard I Scher
Journal:  Cancer Res       Date:  2012-09-12       Impact factor: 12.701

6.  Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.

Authors:  Craig L Doig; Sebastiano Battaglia; Farhat L Khanim; Christopher M Bunce; Moray J Campbell
Journal:  J Steroid Biochem Mol Biol       Date:  2015-09-30       Impact factor: 4.292

7.  N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.

Authors:  Maša Sinreih; Izidor Sosič; Nataša Beranič; Samo Turk; Adegoke O Adeniji; Trevor M Penning; Tea Lanišnik Rižner; Stanislav Gobec
Journal:  Bioorg Med Chem Lett       Date:  2012-07-22       Impact factor: 2.823

Review 8.  AKR1C3 as a target in castrate resistant prostate cancer.

Authors:  Adegoke O Adeniji; Mo Chen; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2013-06-06       Impact factor: 4.292

9.  A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.

Authors:  Phumvadee Wangtrakuldee; Adegoke O Adeniji; Tianzhu Zang; Ling Duan; Buddha Khatri; Barry M Twenter; Michelle A Estrada; Tyler F Higgins; Jeffrey D Winkler; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-11       Impact factor: 4.292

Review 10.  Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.

Authors:  Trevor M Penning
Journal:  Expert Opin Ther Pat       Date:  2017-09-19       Impact factor: 6.674

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.